The ASX 200 has fallen on Tuesday despite surges across the board in the United States and as a major pharmaceutical company surges.

The index fell 0.4 per cent in the first 45 minutes of trading.

Telix Pharamaceuticals has jumped five per cent after announcing it has reached an agreement with the US Food and Drug Administration to resubmit an application for its brain cancer imaging agent called Pixclara.

The FDA earlier this year rejected the application for Pixclara until Telix could provide further evidence about its benefits, sending the company’s share price plummeting.

The company received feedback from the FDA which includes analysis that Telix believes can help it receive approval.

“We remain steadfastly focused on our goal of bringing this important imaging agent to patients

See Full Page